Nucleoside inhibitor-treatment-naïve adult & adolescent ≥16 yr 0.5 mg once daily.
Adult & adolescent ≥16 yr w/ history of hepatitis B viremia while receiving lamivudine or known lamivudine or telbivudine resistance substitutions rtM204I/V w/ or w/o rtL180M, rtL80I/V, or rtV173L 1 mg once daily.
Adult patient w/ CrCl ≥50 mL/min Usual dose: 0.5 mg once daily. Lamivudine-refractory or decompensated liver disease: 1 mg once daily;
CrCl 30 to <50 mL/min Usual dose: 0.5 mg every 48 hr. Lamivudine-refractory or decompensated liver disease: 0.5 mg once daily, or 1 mg every 48 hr;
CrCl 10 to <30 mL/min Usual dose: 0.5 mg every 72 hr. Lamivudine-refractory or decompensated liver disease: 1 mg every 72 hr;
CrCl <10 mL/min, hemodialysis or CAPD Usual dose: 0.5 mg every 7 days. Lamivudine-refractory or decompensated liver disease: 1 mg every 7 days. If administered on a hemodialysis day, administer Hepavance after the hemodialysis session.
Sign Out
